What is the best next-step management for a 66-year-old patient with severe Crohn’s disease on Entyvio (vedolizumab), a colostomy for fibrotic disease, receiving total parenteral nutrition and oral intake, who is being discharged after treatment for pneumonia and bloodstream fungal infection with appropriate antibiotics and systemic antifungals?

Management of Complex Crohn's Disease Patient Post-Fungemia

Continue vedolizumab maintenance therapy and optimize nutritional support while closely monitoring for infection recurrence. 1

Biologic Therapy Management

Vedolizumab should be continued as maintenance therapy given its established efficacy in moderate-to-severe Crohn's disease and favorable safety profile, particularly relevant in this immunocompromised patient. 1

• The Canadian Association of Gastroenterology strongly recommends continued vedolizumab therapy in patients who have achieved symptomatic response to maintain complete remission (strong recommendation, moderate-quality evidence). 1
• Vedolizumab's gut-selective mechanism (α4β7 integrin blockade) provides a theoretical safety advantage over systemic immunosuppression in patients with recent serious infections. 1, 2
• The FDA label notes vedolizumab treatment is not recommended in patients with active, severe infections until controlled, but this patient has completed appropriate antimicrobial therapy and is being discharged. 2

Infection Risk Considerations

• Real-world data show serious infection rates of approximately 13 per 100 patient-years with vedolizumab, which is acceptable given disease severity. 3
• No evidence of progressive multifocal leukoencephalopathy (PML) or reactivation of latent tuberculosis/hepatitis B has been demonstrated with vedolizumab. 4
• The gut-selective nature makes vedolizumab preferable to anti-TNF therapy in older patients where infection and malignancy are concerns. 1

Nutritional Management

Total parenteral nutrition (TPN) should be continued with close monitoring and optimization by a registered dietitian. 1

• TPN plays a critical role in IBD patients with chronic intestinal failure, which this patient demonstrates given the colostomy for fibrotic disease and need for supplementation despite oral intake. 1
• The 2024 AGA Clinical Practice Update emphasizes that all IBD patients warrant regular screening for malnutrition through assessment of unintended weight loss, edema, and muscle mass loss. 1
• Exclusive enteral nutrition may be considered as adjunctive therapy in malnourished Crohn's disease patients, though this patient's colostomy and fibrotic disease may limit applicability. 1

Nutritional Optimization Strategy

• Transition from TPN to customized hydration management (IV electrolyte support and/or oral rehydration solutions) should be attempted when possible to decrease long-term complications. 1
• Consider glucagon-like peptide-2 agonists to facilitate transition from TPN if short bowel syndrome physiology is present. 1
• Registered dietitian involvement is essential for optimal nutrition assessment and management in this complex patient. 1

Infection Surveillance

Implement heightened infection monitoring given recent fungemia and ongoing immunosuppression. 1, 2

• Monitor for signs of recurrent infection including fever, new respiratory symptoms, or changes in clinical status. 1
• Consider withholding vedolizumab if severe infection develops during treatment, though this should be balanced against Crohn's disease activity. 2
• Ensure all immunizations are updated according to current guidelines before continuing biologic therapy. 2

Disease Activity Assessment

Evaluate for symptomatic response to vedolizumab between 10-14 weeks to determine need to modify therapy. 1

• The Canadian guidelines suggest this timeframe specifically for vedolizumab (conditional recommendation, very low-quality evidence). 1
• Given the patient's fibrotic disease with colostomy, focus on clinical symptoms, biomarkers (C-reactive protein, fecal calprotectin if applicable), and quality of life measures rather than endoscopic assessment. 5

Surgical Considerations

Maintain close liaison with colorectal surgery given fibrotic disease and colostomy. 1

• Surgery for CD patients with intestinal obstruction not improving with medical therapy may require stricturoplasty and/or resection. 1
• Nutritional support before and after any future surgery is essential in this patient with chronic malnutrition. 1
• Vedolizumab may help prevent postoperative recurrence if additional resection becomes necessary. 6

Common Pitfalls to Avoid

• Do not discontinue vedolizumab prematurely based solely on recent infection history, as the patient has completed appropriate antimicrobial therapy and vedolizumab has a favorable safety profile. 1, 2
• Do not neglect nutritional assessment - malnutrition is underrecognized in IBD and requires ongoing monitoring with dietitian involvement. 1
• Do not switch biologics without adequate trial - vedolizumab requires 10-14 weeks for full assessment of response. 1
• Avoid corticosteroids for maintenance therapy as they are ineffective and increase infection risk in this already vulnerable patient. 1